Goldman Sachs analyst Scott Fidel initiates coverage on BrightSpring Health (NASDAQ: BTSG) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage